AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026PRNewsWire • 09/30/26
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026PRNewsWire • 09/30/26
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressPRNewsWire • 09/30/26
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 09/29/26
AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical DevelopmentPRNewsWire • 09/29/26
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability ConsortiumBusiness Wire • 09/29/26
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/25/26
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?The Motley Fool • 09/25/26
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade24/7 Wall Street • 09/25/26
Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a DecadeThe Motley Fool • 09/24/26
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic ArthritisZacks Investment Research • 09/22/26
Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation ApproachPRNewsWire • 09/22/26